EBS (Emergent BioSolutions) COGS-to-Revenue : 0.42 (As of Mar. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions COGS-to-Revenue?

Emergent BioSolutions's Cost of Goods Sold for the three months ended in Mar. 2025 was $88.5 Mil. Its Revenue for the three months ended in Mar. 2025 was $209.1 Mil.

Emergent BioSolutions's COGS to Revenue for the three months ended in Mar. 2025 was 0.42.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Emergent BioSolutions's Gross Margin % for the three months ended in Mar. 2025 was 57.68%.

Emergent BioSolutions COGS-to-Revenue Historical Data

The historical data trend for Emergent BioSolutions's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions COGS-to-Revenue Chart

Emergent BioSolutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.37

0.46

0.64

0.69

0.67

Emergent BioSolutions Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.49	1.19	0.43	0.62	0.42

Emergent BioSolutions COGS-to-Revenue Calculation

Emergent BioSolutions's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	681.3	/	1013.6
	=	0.67

Emergent BioSolutions's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	88.5	/	209.1
	=	0.42

Emergent BioSolutions (NYSE:EBS) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Emergent BioSolutions's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	88.5 / 209.1
	=	57.68 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Emergent BioSolutions COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

0IGA:UK ER4:Germany ER4:Germany

Address

300 Professional Drive, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Executives

Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Neal Franklin Fowler	director	C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Marvin L White	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
William Hartzel	officer: SVP, Bioservices	400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii	officer: Interim CEO	EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Paul Anthony Williams	officer: SVP, Products Business	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal	director	C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Glessner Coleen	officer: EVP, Quality & Ethics, and CPL	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox	officer: EVP, Ext Aff, GC, Corp Sec	400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl	officer: EVP, Chief Financial Officer	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey	officer: EVP, BioDefense Division	2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853